

EudraCT: 2014-000918-61

Local R&I Number: ON/2012/4234

CONCEPT Trial: A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metastatic breast cancer.

The results of the trial which includes data collected up to April 2021 can be found in: *The Breast*, Vol. 66, 69-76 2022. Authors: Bahl A, Wilson W, Ball J, Renninson E, Dubey S, Bravo A, Foulstone E, Spensley S, Bowen R, Mansi J, Waters S, Riddle P, Wheatley D, Stephens P, Bezecny P, Madhusudan S, Verrill M, Braybrooke J, Comins C, Mohan V, Gee A, Kirk H, Markham A, Evans H, Watson E, Callaway M, Pearson S, Hackshaw A, Churn M.

A link to the article is available here:

[Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer](#)

Summary results with 5 year outcomes : [Study Details | NCT03048942 | Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | ClinicalTrials.gov](#)